T细胞免疫疗法通常以两类抗原为靶向抗原：私有抗原和公共抗原。公共抗原是指在多个患者中共有的抗原，其中肿瘤相关抗原（TAA）指该抗原在肿瘤细胞中高表达，在健康细胞中也存在但表达水平较低的抗原。
目前有许多肿瘤相关抗原及肿瘤特异性抗原被发现，以TAA为目标的靶向治疗是癌症治疗的重要途径。市场上已经有几种依赖此机制的癌症免疫治疗药物，他们在临床上非常有效。开发针对TAA的药物仍然是一个非常活跃的研究领域。目前有非常多的针对不同种类的肿瘤类型的靶向药物正在进行临床前或者临床检测。针对TAA的抗体不仅可以通过ADCC效应直接杀死肿瘤细胞，也可以作为诊断标记物或者创新性的增加传统癌症疗法的靶向性。
| 靶点 | 产品货号 | 产品名称 |
|
CEACAM
|
GM-30164AB
|
Anti-H_CEACAM1(CD66a) hIgG4 Antibody(MK-6018)
|
|
CEACAM
|
GM-28531AB
|
Anti-CEA hIgG1 Antibody(Cibisatamab)
|
|
CEACAM
|
GM-51007AB
|
Anti-CEACAM7 hIgG4 Antibody(2869)
|
|
CEACAM
|
GM-30166AB
|
Anti-H_CEACAM6(CD66c) hIgG1 Antibody(Tinurilimab)
|
|
SEZ6
|
GM-86544AB
|
Anti-SEZ6 hIgG1 Antibody(ABBV-011)
|
|
IL13RA2
|
GM-86015AB
|
Anti-IL13RA2 hIgG1 Antibody（61H8C1）
|
|
TSPAN8
|
GM-82623AB
|
Anti-TSPAN8 mIgG2b Antibody(Ts29.2)
|
|
CD38
|
GM-27202AB
|
Anti-CD38 hIgG1 Antibody(Daratumumab)
|
|
CDH17
|
GM-75321AB
|
Anti-CDH17 hIgG1 Antibody(VHHl-28BB)
|
|
CDH17
|
GM-52672AB
|
Anti-CDH17 hIgG1 Antibody(BI-905711)
|
|
F3(CD142)
|
GM-28928AB
|
Anti-H_F3(CD142) hIgG1 Antibody(Tisotumab)
|
|
CA9(CAIX)
|
GM-27130AB
|
Anti-H_CAIX hIgG1 Antibody(girentuximab)
|
|
ALPPL2 ALPP
|
GM-58773AB
|
Anti-ALPPL2 mIgG2a antibody(SGN-ALPV)
|
|
ALPPL2 ALPP
|
GM-58774AB
|
Anti-ALPPL2 hIgG1 antibody(SGN-ALPV)
|
|
ALPPL2 ALPP
|
GM-86291MAB
|
Anti-H_ALPPL2 hIgG1 Reference Antibody（h12F3）
|
|
PTK7
|
GM-56186AB
|
Anti-PTK7 hIgG1 Antibody(Cofetuzumab)
|
|
CD4
|
GM-28752AB
|
Anti-H_CD4 hIgG1 Antibody(Tregalizumab)
|
|
TM4SF1
|
GM-59885AB
|
Anti-TM4SF1 hIgG1 Antibody(hAGX-A01H1L10&8G4)
|
|
TM4SF1
|
GM-59881AB
|
Anti-TM4SF1 hIgG1 Antibody(hAGX-A07H2L5)
|
|
LY6G6D
|
GM-58917AB
|
Anti-LY6G6D hIgG1 Antibody(20A12 .QNTv12)
|
|
FAP
|
GM-30156AB
|
Anti-H_FAP hIgG1 Antibody(Simlukafusp)
|
|
NFRSF8(CD30)
|
GM-28856AB
|
Anti-H_TNFRSF8(CD30) hIgG1 Antibody(Brentuximab)
|
|
GPA33
|
GM-52271AB
|
Anti-GPA33 hIgG1 Antibody(DART-2)
|
|
GPA33
|
GM-50417AB
|
Anti-H_GPA33 hIgG1 Antibody(A2)
|
|
DLL
|
GM-51820AB
|
Anti-DLL4 hIgG1 Antibody(MLCK-2(ABL-001)
|
|
DLL
|
GM-51815AB
|
Anti-DLL4 hIgG2 Antibody(Navicixizumab)
|
|
DLL
|
GM-26560AB
|
Anti-H_DLL3 hIgG1 Antibody(Rovalpituzumab)
|
|
MUC1
|
GM-28930AB
|
Anti-H_MUC1(CD227)hIgG1 Antibody(Clivatuzumab)
|
|
CD19
|
GM-28777AB
|
Anti-H_CD19 hIgG1/hIgG2 Antibody(Tafasitamab)
|
|
CD22(SIGLEC2)
|
GM-31561AB
|
Anti-H_CD22 hIgG1 Antibody(Pinatuzumab)
|
|
GPC3
|
GM-28751AB
|
Anti-GPC3 hIgG1 Antibody(Codrituzumab)
|
|
CLEC12A
|
GM-52592AB
|
Anti-CLEC12A hIgG1 Antibody（H6e7）
|
|
BCMA
|
GM-52396AB
|
Anti-BCMA hIgG1 Antibody(Belantamab)
|
|
BCMA
|
GM-49486AB
|
Anti-BCMA hIgG1 Antibody(SEA-BCMA)
|
|
BCMA
|
GM-49476AB
|
Anti-BCMA hIgG4 Antibody(BCMB69)
|
|
CDH6
|
GM-46607AB
|
Anti-H_CDH6 hIgG1 Antibody(H01L02)
|
|
FOLR1
|
GM-27354AB
|
Anti-FOLR1 hIgG1 Antibody(Mirvetuximab)
|
|
FOLR1
|
GM-86372MAB
|
Anti-H_FOLR1 hIgG1 Reference Antibody(Mirvebio)
|
|
FOLH1(PSMA)
|
GM-27353AB
|
Anti-FOLH1(PSMA) hIgG1 Antibody(Rosopatamab)
|
|
SLC34A2
|
GM-26828AB
|
Anti-SLC34A2 hIgG1 Antibody(XMT-1536)
|
|
GUCY2C
|
GM-28860AB
|
Anti-H_GUCY2C hIgG1 Antibody(Indusatumab)
|
|
TROP2
|
GM-26561AB
|
Anti-H_TROP2 hIgG1 Antibody(datopotamab)
|
|
AMHR2
|
GM-27802AB
|
Anti-AMHR2 hIgG1 Antibody(Murlentamab)
|
|
CD123(IL3RA)
|
GM-27123AB
|
Anti-H_CD123 hIgG2 Antibody(Talacotuzumab)
|
|
MSLN
|
GM-24027AB
|
Anti-H_MSLN hIgG1 Antibody(Amatuximab)
|
|
CDH3
|
GM-46573AB
|
Anti-H_CDH3 hIgG1 Antibody
|
|
NECTIN4
|
GM-23369AB
|
Anti-H_Nectin4 hIgG1 Antibody (Enfortumab)
|
|
CEACAM8
|
GM-49164AB
|
Anti-CEACAM8 hIgG1 Antibody(Besilesomab)
|
|
TROP2
|
GM-52040AB
|
Anti-TROP2 hIgG1 Antibody(Hu2G10-5)
|
|
TROP2
|
GM-87498MAB
|
Anti-Trop2 hIgG1 Reference Antibody(Datbio)
|
|
TROP2
|
GM-87499MAB
|
Anti-Trop2 hIgG1 Reference Antibody (Sacbio)
|
| 靶点 | 产品货号 | 产品名称 |
|
CEACAM
|
GM-30164AB
|
Anti-H_CEACAM1(CD66a) hIgG4 Antibody(MK-6018)
|
|
CEACAM
|
GM-28531AB
|
Anti-CEA hIgG1 Antibody(Cibisatamab)
|
|
CEACAM
|
GM-51007AB
|
Anti-CEACAM7 hIgG4 Antibody(2869)
|
|
CEACAM
|
GM-30166AB
|
Anti-H_CEACAM6(CD66c) hIgG1 Antibody(Tinurilimab)
|
|
SEZ6
|
GM-86544AB
|
Anti-SEZ6 hIgG1 Antibody(ABBV-011)
|
|
IL13RA2
|
GM-86015AB
|
Anti-IL13RA2 hIgG1 Antibody（61H8C1）
|
|
TSPAN8
|
GM-82623AB
|
Anti-TSPAN8 mIgG2b Antibody(Ts29.2)
|
|
CD38
|
GM-27202AB
|
Anti-CD38 hIgG1 Antibody(Daratumumab)
|
|
CDH17
|
GM-75321AB
|
Anti-CDH17 hIgG1 Antibody(VHHl-28BB)
|
|
CDH17
|
GM-52672AB
|
Anti-CDH17 hIgG1 Antibody(BI-905711)
|
|
F3(CD142)
|
GM-28928AB
|
Anti-H_F3(CD142) hIgG1 Antibody(Tisotumab)
|
|
CA9(CAIX)
|
GM-27130AB
|
Anti-H_CAIX hIgG1 Antibody(girentuximab)
|
|
ALPPL2 ALPP
|
GM-58773AB
|
Anti-ALPPL2 mIgG2a antibody(SGN-ALPV)
|
|
ALPPL2 ALPP
|
GM-58774AB
|
Anti-ALPPL2 hIgG1 antibody(SGN-ALPV)
|
|
ALPPL2 ALPP
|
GM-86291MAB
|
Anti-H_ALPPL2 hIgG1 Reference Antibody（h12F3）
|
|
PTK7
|
GM-56186AB
|
Anti-PTK7 hIgG1 Antibody(Cofetuzumab)
|
|
CD4
|
GM-28752AB
|
Anti-H_CD4 hIgG1 Antibody(Tregalizumab)
|
|
TM4SF1
|
GM-59885AB
|
Anti-TM4SF1 hIgG1 Antibody(hAGX-A01H1L10&8G4)
|
|
TM4SF1
|
GM-59881AB
|
Anti-TM4SF1 hIgG1 Antibody(hAGX-A07H2L5)
|
|
LY6G6D
|
GM-58917AB
|
Anti-LY6G6D hIgG1 Antibody(20A12 .QNTv12)
|
|
FAP
|
GM-30156AB
|
Anti-H_FAP hIgG1 Antibody(Simlukafusp)
|
|
NFRSF8(CD30)
|
GM-28856AB
|
Anti-H_TNFRSF8(CD30) hIgG1 Antibody(Brentuximab)
|
|
GPA33
|
GM-52271AB
|
Anti-GPA33 hIgG1 Antibody(DART-2)
|
|
GPA33
|
GM-50417AB
|
Anti-H_GPA33 hIgG1 Antibody(A2)
|
|
DLL
|
GM-51820AB
|
Anti-DLL4 hIgG1 Antibody(MLCK-2(ABL-001)
|
|
DLL
|
GM-51815AB
|
Anti-DLL4 hIgG2 Antibody(Navicixizumab)
|
|
DLL
|
GM-26560AB
|
Anti-H_DLL3 hIgG1 Antibody(Rovalpituzumab)
|
|
MUC1
|
GM-28930AB
|
Anti-H_MUC1(CD227)hIgG1 Antibody(Clivatuzumab)
|
|
CD19
|
GM-28777AB
|
Anti-H_CD19 hIgG1/hIgG2 Antibody(Tafasitamab)
|
|
CD22(SIGLEC2)
|
GM-31561AB
|
Anti-H_CD22 hIgG1 Antibody(Pinatuzumab)
|
|
GPC3
|
GM-28751AB
|
Anti-GPC3 hIgG1 Antibody(Codrituzumab)
|
|
CLEC12A
|
GM-52592AB
|
Anti-CLEC12A hIgG1 Antibody（H6e7）
|
|
BCMA
|
GM-52396AB
|
Anti-BCMA hIgG1 Antibody(Belantamab)
|
|
BCMA
|
GM-49486AB
|
Anti-BCMA hIgG1 Antibody(SEA-BCMA)
|
|
BCMA
|
GM-49476AB
|
Anti-BCMA hIgG4 Antibody(BCMB69)
|
|
CDH6
|
GM-46607AB
|
Anti-H_CDH6 hIgG1 Antibody(H01L02)
|
|
FOLR1
|
GM-27354AB
|
Anti-FOLR1 hIgG1 Antibody(Mirvetuximab)
|
|
FOLR1
|
GM-86372MAB
|
Anti-H_FOLR1 hIgG1 Reference Antibody(Mirvebio)
|
|
FOLH1(PSMA)
|
GM-27353AB
|
Anti-FOLH1(PSMA) hIgG1 Antibody(Rosopatamab)
|
|
SLC34A2
|
GM-26828AB
|
Anti-SLC34A2 hIgG1 Antibody(XMT-1536)
|
|
GUCY2C
|
GM-28860AB
|
Anti-H_GUCY2C hIgG1 Antibody(Indusatumab)
|
|
TROP2
|
GM-26561AB
|
Anti-H_TROP2 hIgG1 Antibody(datopotamab)
|
|
AMHR2
|
GM-27802AB
|
Anti-AMHR2 hIgG1 Antibody(Murlentamab)
|
|
CD123(IL3RA)
|
GM-27123AB
|
Anti-H_CD123 hIgG2 Antibody(Talacotuzumab)
|
|
MSLN
|
GM-24027AB
|
Anti-H_MSLN hIgG1 Antibody(Amatuximab)
|
|
CDH3
|
GM-46573AB
|
Anti-H_CDH3 hIgG1 Antibody
|
|
NECTIN4
|
GM-23369AB
|
Anti-H_Nectin4 hIgG1 Antibody (Enfortumab)
|
|
CEACAM8
|
GM-49164AB
|
Anti-CEACAM8 hIgG1 Antibody(Besilesomab)
|
|
TROP2
|
GM-52040AB
|
Anti-TROP2 hIgG1 Antibody(Hu2G10-5)
|
|
TROP2
|
GM-87498MAB
|
Anti-Trop2 hIgG1 Reference Antibody(Datbio)
|
|
TROP2
|
GM-87499MAB
|
Anti-Trop2 hIgG1 Reference Antibody (Sacbio)
|
T细胞免疫疗法通常以两类抗原为靶向抗原：私有抗原和公共抗原。公共抗原是指在多个患者中共有的抗原，其中肿瘤相关抗原（TAA）指该抗原在肿瘤细胞中高表达，在健康细胞中也存在但表达水平较低的抗原。
目前有许多肿瘤相关抗原及肿瘤特异性抗原被发现，以TAA为目标的靶向治疗是癌症治疗的重要途径。市场上已经有几种依赖此机制的癌症免疫治疗药物，他们在临床上非常有效。开发针对TAA的药物仍然是一个非常活跃的研究领域。目前有非常多的针对不同种类的肿瘤类型的靶向药物正在进行临床前或者临床检测。针对TAA的抗体不仅可以通过ADCC效应直接杀死肿瘤细胞，也可以作为诊断标记物或者创新性的增加传统癌症疗法的靶向性。
